Sangamo Therapeutics Inc (LTS:0R1D)
$ 1.9196 -0.0403 (-2.06%) Market Cap: 406.86 Mil Enterprise Value: 395.39 Mil PE Ratio: 0 PB Ratio: 10.37 GF Score: 34/100

Q2 2023 Sangamo Therapeutics Inc Earnings Call Transcript

Aug 08, 2023 / 08:30PM GMT
Release Date Price: $1.14 (-2.56%)
Operator

Good day, and thank you for standing by. Welcome to the Sangamo Second Quarter 2023 Teleconference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Louise Wilkie, Vice President of Investor Relations and Corporate Communications. Please go ahead.

Louise Wilkie
Sangamo Therapeutics, Inc. - VP of IR & Corporate Communications

Thank you. Good afternoon. I'm Louise Wilkie, Sangamo's Vice President of Investor Relations and Corporate Communications. Thank you for joining us on the call today. On this call are several members of the Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Mark McClung, Chief Operating Officer; Prathyusha Duraibabu, Chief Financial Officer; Jason Fontenot, Chief Scientific Officer; Nathalie Dubois-Stringfellow, Chief Development Officer; and Lisa Rojkjaer, Chief Medical Officer. Slides from our corporate presentation can be found at our website, sangamo.com, under the Investors &

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot